George N. Papaliodis, M.D.

Harvard Medical School

Associate Professor of Ophthalmology

Massachusetts Eye and Ear

Director, Immunology and Uveitis Service
Associate Scientist

Research Summary

Research Summary

Board-certified in internal medicine and ophthalmology, Dr. Papaliodis specializes in the treatment of systemic diseases that induce ocular inflammation. He has been the director of the Ocular Immunology and Uveitis service since 2005.  His research has focused on attempting to identify disease mechanisms which can induce uveitis and novel treatments for intraocular inflammation. He has studied serum biomarkers and genetics in ocular sarcoidosis along with the role of vitamin D in ocular inflammatory disorders.  He has been an investigator in multiple drug company sponsored clinical trials to establish the efficacy of therapeutic agents for uveitis.  In collaboration with Dr. John Kempen, he is currently working on assessing factors that may influence the development of ocular complications in those who have intraocular inflammation. 

Education

1992: BS, Chemistry, Physics, and Biology, summa cum laude, Texas Christian University

1995: MD, University of Texas Southwestern Medical School

Postgraduate Training

1996: Internship, Internal Medicine, Massachusetts General Hospital

1999: Residency, Ophthalmology, University of Texas Southwestern

2001: Residency, Internal Medicine, Massachusetts General Hospital

2002: Fellowship, Ocular Immunology and Uveitis, Massachusetts Eye and Ear

Academic Appointments

2018-present: Associate Professor of Ophthalmology, Harvard Medical School

2011-2018: Assistant Professor of Ophthalmology, Harvard Medical School

2005-2011: Instructor in Ophthalmology, Harvard Medical School

2003-2005: Instructor in Medicine, Harvard Medical School

2002-2003: Instructor in Ophthalmology, Harvard Medical School

Professional Memberships

American Uveitis Society

Honors

Massachusetts Eye and Ear Resident Teaching Award



Publications

Selected Publications

For a full publication list, please see his CV.

Golimumab for the treatment of refractory juvenile idiopathic arthritis-associated uveitis. William M, Faez S, Papaliodis GN, Lobo AM. J Ophthalmic Inflamm Infect. 2012 Dec;2(4):231-3.

Treatment of seronegative spondyloarthropathy-associated uveitis with golimumab: retrospective case series. Faez S, Lobo AM, Sobrin L, Papaliodis GNClin Experiment Ophthalmol. 2014 May-Jun;42(4):392-5.

Role of OCT in the diagnosis and management of macular edema from uveitis. Hunter RS, Skondra D, Papaliodis G, Sobrin L. Semin Ophthalmol. 2012 Sep-Nov;27(5-6):236-41.

Eales' Disease. Papaliodis GN. [Online publication, Uptodate.com]. 2011-present

Paraneoplastic conjunctival cicatrization: two different pathogenic types. Ahuero AE, Jakobiec FA, Bhat P, Ciralsky JB, Papaliodis GNOphthalmology. 2010 Apr;117(4):659-64.

View a complete list of publications on pubmed.gov>>